MedPath

Simulated Clinical Use Testing on Safety Lancets (Test A)

Not Applicable
Completed
Conditions
Needle Stick
Interventions
Device: Acti-Lance safety lancet
Device: ergoLance safety lancet
Registration Number
NCT03807635
Lead Sponsor
HTL-Strefa S.A.
Brief Summary

A simulated clinical use testing on the HTL-Strefa's safety lancets

Detailed Description

This study aims to evaluate the safety of the use of the safety lancets: ergoLance and Acti-Lance in the prevention of NSI and to evaluate the user's opinion with regards to the handling characteristics of the medical devices.

The simulated use clinical study will involve healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples and lay persons.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria

The inclusion criteria for HCP and lay person evaluators have been chosen based on FDA guidance:

  • (HCP evaluators only) - evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts)
  • evaluators will be United States (US) residents
  • evaluators can read, write, and speak English
  • evaluators are at least 18 years old
  • evaluators are able to understand and provide signed consent for the study
  • evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires.
  • evaluators have no concerns about the ability to perform the simulated skin pricking.

Lay person evaluators will have a diverse range of ages (18+ years), socioeconomic statuses, and race/ethnic backgrounds. UL-Wiklund will recruit some lay person evaluators with reduced vision and dexterity. Users without safety lancet experience may also be included in this simulated clinical use study.

Exclusion Criteria

HCPs:

  • They do not routinely use safety lancets to collect capillary blood samples,
  • They cannot read, write, and speak English,
  • They or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or
  • They have participated in a product evaluation or marketing study involving safety lancets within the last six months

Lay people:

  • They cannot read, write, and speak English,
  • They or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or
  • They have participated in a product evaluation or marketing study involving safety lancets within the last six months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
simulation of skin pricking type 610Acti-Lance safety lancetThe evaluator simulated the capillary blood sampling with the safety lancet type 610
simulation of skin pricking type 450ergoLance safety lancetThe evaluator simulated the capillary blood sampling with the safety lancet type 450
Primary Outcome Measures
NameTimeMethod
The true failure rate of the tested devicesAt time of testing, up to 90 minutes
Effectiveness of the safety lancet's sharps injury prevention featuresAt time of testing, up to 90 minutes

Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.

Secondary Outcome Measures
NameTimeMethod
Subjective assessments regarding evaluators' interactions with the tested safety lancetsAt time of testing, up to 90 minutes

Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.

Safety of the devices based on the evaluators' assessments (five-point response scale)At time of testing, up to 90 minutes

Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure any and all observed needlestick injuries and device malfunctions. Numbers assigned to Likert scale express a "greater than" relationship.

Various aspects of the ease of use.At time of testing, up to 90 minutes

Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.

Any handling, usability questions / issues associated with the deviceAt time of testing, up to 90 minutes

Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.

Trial Locations

Locations (2)

UL LLC

🇺🇸

Chicago, Illinois, United States

Schlesinger Associates

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath